Abstract
Amiodarone is the "gold standard" for current antiarrhythmic therapy because it combines efficacy with good hemodynamic and electrophysiological tolerance. Amiodarone is effective against both atrial and ventricular arrhythmias by intravenous (i.v.) or oral route. However, the i.v. formulation has limitations. Therefore, we identified SAR114646A, an amiodarone-like antiarrhythmic agent with good aqueous solubility suitable for i.v. application. Patch–clamp experiments were performed with isolated cardiomyocytes from guinea pigs and rats. In guinea pig ventricular cardiomyocytes, the fast Na+ channel and the L-type Ca2+ channels were blocked by SAR114646A with half-maximal concentrations (IC50) of 2.0 and 1.1 μM, respectively. The tail current of the fast activating rectifying potassium channel IKr was blocked with an IC50 value of 0.6 μM, whereas the IC50 values for inhibition of the IKs and IK1 channels was >10 μM. ATP-sensitive K+ channels were evoked by application of the channel opener rilmakalim (3 μM). SAR114646A blocked this current with an IC50 value of 2.8 μM. In guinea pig atrial cardiomyocytes, carbachol (1 μM) was used to activate the IKACh and SAR114646A inhibited this current with IC50 of 36.5 nM. The transient outward current Ito and the sustained current Isus were investigated in rat ventricular myocytes. SAR114646A blocked these currents with IC50 of 1.8 and 1.2 μM, respectively. When expressed in Chinese hamster ovary cells, the currents hKv1.5 and hHCN4 were inhibited with IC50 values of 1.1 and 0.4 μM, respectively. Micropuncture experiments in isolated rabbit left atria revealed that SAR114646A prolonged the 50% repolarization significantly at 3 and 10 μM. In guinea pig papillary muscle, the APD at 90% of repolarization was slightly prolonged at 3 and 10 μM. SAR114646A demonstrates antiarrhythmic activity in anaesthetised rats, subjected to 5 min ischemia followed by 10 min reperfusion, where 1 mg/kg of SAR114646A applied as i.v. bolus 5 min prior to ischemia, decreased mortality to 0% compared to 80% under control conditions. In conclusion, SAR114646A is a multichannel blocker with improved water solubility, compared to amiodarone. In contrast to amiodarone, SAR114646A also blocks the K+ channels Ito and Isus. A potent antiarrhythmic effect as observed in rats can also be expected in other animal models.
Similar content being viewed by others
References
Allessie MA, Lammers WJ, Bonke IM, Hollen J (1984) Intra-atrial reentry as a mechanism for atrial flutter induced by acetylcholine and rapid pacing in the dog. Circulation 70:123–135
Billman GE, Englert HC, Schölkens BA (1998) HMR 1883, a novel cardioselective inhibitor of the ATP-sensitive potassium channel. Part II: effects on susceptibility to ventricular fibrillation induced by myocardial ischemia in conscious dogs. J Pharmacol Exp Ther 286:1465–1473
Billman GE, Kukielka M, Del Rio CL, Goegelein H (2008) Effect of the novel amiodarone-like compound SAR114646A on susceptibility to sudden death: prevention of ventricular fibrillation induced by myocardial ischemia. Europ Heart J 29:633
Bucchi A, Tognati A, Milanesi R, Baruscotti M, DiFrancesco D (2006) Properties of ivabradine-induced block of HCN1 and HCN4 pacemaker channels. J Physiol 572:335–346
Chen YJ, Chen SA, Tai CT, Wen ZC, Feng AN, Ding YA, Chang MS (1998) Role of atrial electrophysiology and autonomic nervous system in patients with supraventricular tachycardia and paroxysmal atrial fibrillation. J Am Coll Cardiol 32:732–738
Chevalier P, Durand-Dubief A, Burri H, Cucherat M, Kirkorian G, Touboul P (2003) Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. J Am Coll Cardiol 41:255–262
Clemo HF, Wood MA, Gilligan DM, Ellenbogen KA (1998) Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol 81:594–598
Close B, Banister K, Baumans V, Bernoth EM, Bromage N, Bunyan J, Erhardt W, Flecknell P, Gregory N, Hackbarth H, Morton D, Warwick C (1997) Recommendations for euthanasia of experimental animals: part 2. DGXT of the European Commission. Lab Anim 31:1–32
Dobrev D, Friedrich A, Voigt N, Jost N, Wettwer E, Christ T, Knaut M, Ravens U (2005) The G protein-gated potassium current I(K, ACh) is constitutively active in patients with chronic atrial fibrillation. Circulation 112:3697–3706
Dorian P, Cass D, Schwartz B, Cooper R, Gelaznikas R, Barr A (2002) Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med 346:884–890
Ehrlich JR, Cha TJ, Zhang L, Chartier D, Villeneuve L, Hebert TE, Nattel S (2004) Characterization of a hyperpolarization-activated time-dependent potassium current in canine cardiomyocytes from pulmonary vein myocardial sleeves and left atrium. J Physiol 557:583–597
Follmer CH, Aomine M, Yeh JZ, Singer DH (1987) Amiodarone-induced block of sodium current in isolated cardiac cells. J Pharmacol Exp Ther 243:187–194
Furukawa T, Kimura S, Furukawa N, Bassett AL, Myerburg RJ (1991) Role of cardiac ATP-regulated potassium channels in differential responses of endocardial and epicardial cells to ischemia. Circ Res 68:1693–1702
Gautier P, Guillemare E, Djandjighian L, Marion A, Planchenault J, Bernhart C, Herbert JM, Nisato D (2004) In vivo and in vitro characterization of the novel antiarrhythmic agent SSR149744C: electrophysiological, anti-adrenergic, and anti-angiotensin II effects. J Cardiovasc Pharmacol 44:244–257
Goegelein H, Gautier P, Tonnerre B, Roccon A, Herbert JM, Wirth KJ, Janiak P, Ruetten H, O’Connor SE (2008) SAR114646A: a water-soluble amiodarone-like compound for i.v. treatment of atrial and ventricular arrhythmias. Europ Heart J 29:635
Gögelein H, Brendel J, Steinmeyer K, Strubing C, Picard N, Rampe D, Kopp K, Busch AE, Bleich M (2004) Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels. Naunyn Schmiedebergs Arch Pharmacol 370:183–192
Goldschlager N, Epstein AE, Naccarelli GV, Olshansky B, Singh B, Collard HR, Murphy E (2007) A practical guide for clinicians who treat patients with amiodarone: 2007. Hear Rhythm 4:1250–1259
Hashimoto N, Yamashita T, Tsuruzoe N (2006) Tertiapin, a selective IKACh blocker, terminates atrial fibrillation with selective atrial effective refractory period prolongation. Pharmacol Res 54:136–141
Heidbüchel H, Callewaert G, Vereecke J, Carmeliet E (1992) Activation of guinea pig atrial muscarinic K+ channels by nucleoside triphosphates in the absence of acetylcholine. J Cardiovasc Electrophysiol 3:457–473
Holmes DS, Zun ZQ, Porter LM, Bernstein NE, Chinitz LA, Artman M, Coetzee WA (2000) Amiodarone inhibits cardiac ATP-sensitive potassium channels. J Cardiovasc Electrophysiol 11:1152–1158
Janse MJ, Wit AL (1989) Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev 69:1049–1169
Kowey PR, Levine JH, Herre JM, Pacifico A, Lindsay BD, Plumb VJ, Janosik DL, Kopelman HA, Scheinman MM (1995) Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group. Circulation 92:3255–3263
Krause E, Englert H, Gögelein H (1995) Adenosine triphosphate-dependent K currents activated by metabolic inhibition in rat ventricular myocytes differ from those elicited by the channel opener rilmakalim. Pflugers Arch 429:625–635
Kudenchuk PJ, Cobb LA, Copass MK, Cummins RO, Doherty AM, Fahrenbruch CE, Hallstrom AP, Murray WA, Olsufka M, Walsh T (1999) Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med 341:871–878
Lalevee N, Nargeot J, Barrere-Lemaire S, Gautier P, Richard S (2003) Effects of amiodarone and dronedarone on voltage-dependent sodium current in human cardiomyocytes. J Cardiovasc Electrophysiol 14:885–890
Levine JH, Massumi A, Scheinman MM, Winkle RA, Platia EV, Chilson DA, Gomes A, Woosley RL (1996) Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. Intravenous Amiodarone Multicenter Trial Group. J Am Coll Cardiol 27:67–75
Li GR, Feng J, Yue L, Carrier M, Nattel S (1996) Evidence for two components of delayed rectifier K+ current in human ventricular myocytes. Circ Res 78:689–696
Liu L, Nattel S (1997) Differing sympathetic and vagal effects on atrial fibrillation in dogs: role of refractoriness heterogeneity. Am J Physiol 273:H805–H816
Lombardo F, Obach RS, Shalaeva MY, Gao F (2002) Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. J Med Chem 45:2867–2876
Lukas A, Antzelevitch C (1993) Differences in the electrophysiological response of canine ventricular epicardium and endocardium to ischemia. Role of the transient outward current. Circulation 88:2903–2915
Manning AS, Bruyninckx C, Ramboux J, Chatelain P (1995) SR 33589, a new amiodarone-like agent: effect on ischemia- and reperfusion-induced arrhythmias in anesthetized rats. J Cardiovasc Pharmacol 26:453–461
Nerbonne JM (2000) Molecular basis of functional voltage-gated K+ channel diversity in the mammalian myocardium. J Physiol 525(Pt 2):285–298
Nishimura M, Follmer CH, Singer DH (1989) Amiodarone blocks calcium current in single guinea pig ventricular myocytes. J Pharmacol Exp Ther 251:650–659
Platou ES, Refsum H (1986) Acute electrophysiologic and blood pressure effects of amiodarone and its solvent in the dog. Acta Pharmacol Toxicol (Copenh) 58:163–168
Sato T, Takizawa T, Saito T, Kobayashi S, Hara Y, Nakaya H (2003) Amiodarone inhibits sarcolemmal but not mitochondrial KATP channels in guinea pig ventricular cells. J Pharmacol Exp Ther 307:955–960
Scheinman MM, Levine JH, Cannom DS, Friehling T, Kopelman HA, Chilson DA, Platia EV, Wilber DJ, Kowey PR (1995) Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group. Circulation 92:3264–3272
Uchida T, Yashima M, Gotoh M, Qu ZL, Garfinkel A, Weiss JN, Fishbein MC, Mandel WJ, Chen PS, Karagueuzian HS (1999) Mechanism of acceleration of functional reentry in the ventricle effects of ATP-sensitive potassium channel opener. Circulation 99:704–712
Varro A, Virag L, Papp JG (1996) Comparison of the chronic and acute effects of amiodarone on the calcium and potassium currents in rabbit isolated cardiac myocytes. Br J Pharmacol 117:1181–1186
Vassallo P, Trohman RG (2007) Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 298:1312–1322
Watanabe Y, Hara Y, Tamagawa M, Nakaya H (1996) Inhibitory effect of amiodarone on the muscarinic acetylcholine receptor-operated potassium current in guinea pig atrial cells. J Pharmacol Exp Ther 279:617–624
Zankov DP, Ding WG, Matsuura H, Horie M (2005) Open-state unblock characterizes acute inhibition of IKs potassium current by amiodarone in guinea pig ventricular myocytes. J Cardiovasc Electrophysiol 16:314–322
Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, Gregoratos G, Klein G, Moss AJ, Myerburg RJ, Priori SG, Quinones MA, Roden DM, Silka MJ, Tracy C, Smith SC Jr, Jacobs AK, Adams CD, Antman EM, Anderson JL, Hunt SA, Halperin JL, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL (2006) ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 48:e247–e346
Acknowledgments
We acknowledge the skillful assistance of Ms. Karin Kopp and Mr. Roland Klein in performing part of the experiments. We want to thank PD Dr. Klaus Steinmeyer for valuable discussion.
Disclosure
All authors are employees of Sanofi-Aventis.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Goegelein, H., Gautier, P., Roccon, A. et al. Effects of the novel amiodarone-like compound SAR114646A on cardiac ion channels and ventricular arrhythmias in rats. Naunyn-Schmiedeberg's Arch Pharmacol 384, 231–244 (2011). https://doi.org/10.1007/s00210-011-0664-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-011-0664-4